FDA Inspection 1260618 — Livzon New North River Pharmaceutical Co., Ltd.
The FDA completed an inspection of Livzon New North River Pharmaceutical Co., Ltd. on December 20, 2024 in Qingyuan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Veterinary.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- December 20, 2024
- Fiscal Year
- 2025
- Product Type
- Veterinary
- Project Area
- Monitoring of Marketed Animal Drugs, Feed, and Devices
- Location
- Qingyuan (China)